Chemical subgroup
L01EF – Cyclin-abhängige Kinasen (CDK)-Inhibitoren
14Decisions
26Patient groups
Added benefit by patient group
- Minor6
- Not proven20
Decisions, newest first
- 2026-08-20VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-06-05KisqaliRibociclibNot proven: 3 of 3 patient groups
- 2023-06-15VerzeniosAbemaciclibMinor
- 2022-12-15IbrancePalbociclibNot proven
- 2022-10-20VerzeniosAbemaciclibNot proven
- 2022-05-19VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-09-03VerzeniosAbemaciclibNot proven
- 2020-08-20KisqaliRibociclibMinor: 2 of 2 patient groups
- 2020-08-20KisqaliRibociclibMinor
- 2019-07-04KisqaliRibociclibNot proven: 5 of 5 patient groups
- 2019-05-02VerzeniosAbemaciclibNot proven
- 2019-05-02VerzeniosAbemaciclibNot proven: 3 of 3 patient groups
- 2019-03-22IbrancePalbociclibNot proven: 2 of 2 patient groups
- 2017-05-18IbrancePalbociclibNot proven
Data status: 2026-10-29